Announcements

(Requests for announcements must be received at least three months before publication.)

2000 ANNUAL MEETING

The AACR’s Annual Meeting is one of the largest and most important annual gatherings of scientists engaged in cancer research worldwide. The next Annual Meeting will take place in San Francisco, CA, April 1–5, 2000. The Chairperson of the Annual Meeting is Peter A. Jones, of the Norris Comprehensive Cancer Center. Co-Chairpersons are Carlos L. Arteaga, Vanderbilt University; Franco M. Muggia, Kaplan Comprehensive Cancer Center; Geoffrey M. Wahl, Salk Institute; and Alice S. Whittemore, Stanford University.

The Program Committee will invite outstanding scientists in the field to organize plenary sessions, symposia, controversy sessions, and meet-the-expert sunrise sessions. It will also review proffered papers submitted by members of the cancer research community and will schedule acceptable ones in minisymposia, poster discussion sessions, and poster sessions. Further program information can be found on the AACR’s Website (http://www.aacr.org).

FUTURE ANNUAL MEETINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

2000 April 1–5, San Francisco, CA
2001 March 24–28, New Orleans, LA
2002 April 6–10, San Francisco, CA

LATE-BREAKING RESEARCH SESSION AT THE AACR ANNUAL MEETING

Time has been set aside for the presentation of a few definitive reports of highly significant and timely findings in the field. Criteria for the selection of these presentations and instructions for submission of abstracts are as follows:

1. The work to be presented must be of major novelty and significance, e.g., the characterization of a new gene in familial cancer or the discovery of a new diagnostic marker, and should not have been previously published in a peer-reviewed scientific journal or presented at a national meeting.

2. The abstract must be sponsored by an AACR member in good standing (dues paid for 2000).

3. Each member in good standing may sponsor only one abstract for this session whether or not he or she has sponsored an abstract last November for the regular annual meeting program. If an associate member is the sponsor, the abstract must also be endorsed by an active or corresponding member in good standing. In this case, the endorser does not forfeit the opportunity to sponsor a late-breaking abstract.


5. Each abstract must be accompanied by a covering letter from the sponsor explaining why the work is novel and significant enough to be considered for this late-breaking research session and certifying that the findings became available after the annual meeting abstract deadline of November 1, 1999. This letter must contain the sponsor’s complete mailing address, FAX number, and E-mail address (if available) so that we can communicate the scheduling decision of the Program Committee.

6. Abstracts and covering letters must be received in the AACR Office by 5:00 p.m. Eastern Standard Time on February 25, 2000. Neither fax nor e-mail transmissions are acceptable. Carrying envelopes should be clearly marked “Late-Breaking Abstract,” and should be addressed to American Association for Cancer Research, Public Ledger Building, Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. If you wish to receive acknowledgment of receipt of your abstract, enclose a self-addressed post card with appropriate postage affixed. Accepted abstracts will not be published since they will be received after the Proceedings of the American Association for Cancer Research has been printed; however, they will be distributed at the session in San Francisco.

7. A special subcommittee of the Program Committee appointed by President Daniel D. Von Hoff will select the papers to be presented. Presenters of accepted papers will be notified via FAX no later than March 15, 2000.

WORKSHOP ON PATHOBIOLOGY OF CANCER

The AACR will sponsor a workshop entitled “Pathobiology of Cancer” at the Keystone Center in Keystone, Colorado, from July 16–23, 2000. This workshop is supported by a generous grant from the National Cancer Institute that will offset the cost of registration, housing, and meals for approximately 100 graduate students and postdoctoral fellows engaged in basic cancer research (including epidemiological studies). A limited number of senior scientists will also be admitted to the workshop upon payment of a registration fee.

This intensive, one-week workshop will provide participants with a background in cancer biology, pathology, and cancer-related disciplines. The program consists of 28 hours of laboratory sessions, 10 hours of lectures, and 4 hours of poster sessions. The Course Director for 2000 is Dr. Ann D. Thor of Northwestern University. She will direct a faculty of outstanding cancer researchers who will head the various laboratory sections and present lectures on recent advances in the field of histopathobiology of cancer and other appropriate scientific disciplines. Information and application forms will be mailed to AACR members in January. Nonmembers should request information and brochures from the AACR office.

WORKSHOP ON MOLECULAR BIOLOGY IN CLINICAL ONCOLOGY

The AACR will sponsor an intensive, one-week summer workshop on molecular biology designed for clinical oncologists in training and in their early academic careers. The workshop will take place at the Given Biomedical Institute in Aspen, Colorado, from June 30–July 7, 2000. Recent advances in molecular biology are becoming more and more relevant to the diagnosis, therapy, and management of cancer patients. The workshop will give clinical oncologists the opportunity to interact closely in an informal setting with experts in the field of molecular biology, learn their language and laboratory techniques, better understand relevant literature, and communicate more effectively with their basic science colleagues.

Michael B. Kastan of St. Jude Children’s Research Hospital, L. Michael Glodé of the University of Colorado School of Medicine, and Kathleen R. Cho of the University of Michigan will serve as chairpersons of the workshop and will invite a distinguished faculty to direct four 2½-hour laboratory sessions and deliver 20 hours of lectures. Generous support from the National Cancer Institute will provide funding for the registration fees and hotel accommodations of 65 physicians in training and oncology fellows. Ten senior clinical oncologists will also be able to attend the workshop upon payment of a registration fee.

Information and application forms will be mailed to AACR members in January. Nonmembers should request brochures from the AACR office.

WORKSHOP ON METHODS IN CLINICAL CANCER RESEARCH

The AACR and the American Society of Clinical Oncology (ASCO) will sponsor a six-day summer workshop on clinical research methods designed for both oncologists in training and senior investigators. The workshop will take place at the Vail Cascade Hotel and Club in Vail, Colorado, from July 29–August 4, 2000. The overall goal of the workshop will be to educate clinical scientists in methods for clinical research and to encourage better clinical trial design so that new cancer treatments can be introduced more rapidly into general medical practice. Major support for this program is provided by the National Cancer Institute. Support is also provided by Bristol-Myers Squibb, Amgen, Hoechst Marion Roussel, and Searle. Funds will be available to offset the registration fees and housing subsistence expenses for 75 clinical trainees to attend the workshop. In addition, 25 clinical investigators at the level of junior faculty will be accepted to the workshop; their registration fees will be waived, and some travel support will be available.

The Workshop Organizing Committee is chaired by Drs. Margaret A. Tempero, H. Kim Lyerly, and Gary M. Clark. They will invite and select a distinguished faculty that will deliver over 20 hours of lectures on a variety of topics in the field and direct several small-group discussion.
sessions in which 15–20 participants can review important aspects of the design of clinical trials. In addition, each participant will be responsible for the preparation of an actual protocol for a clinical trial while attending the workshop. Groups of six to eight students will meet with two assigned faculty members on several occasions during the week to review intermediate drafts of these protocols.

Information and application forms will be mailed to AACR and ASCO members in January. Nonmembers should request brochures from the AACR office.

**AACR SPECIAL CONFERENCES IN CANCER RESEARCH**

A number of meetings are now being organized in the AACR’s series of smaller scientific meetings. Following are the topics, dates, locations, and program committees for these meetings. When full details of each meeting are available, AACR members will be the first to receive complete brochures and application forms for participation in these important conferences. Nonmembers may receive this information by sending their names and addresses to Meetings Mailing List, American Association for Cancer Research, Public Ledger Building, 150 South Independence Mall West, Suite 826, Philadelphia, PA 19106-3483. Up-to-date program information is also available via the Internet at the AACR’s website (http://www.aacr.org/confrnc.html).

**PROGRAMMED CELL DEATH REGULATION: BASIC MECHANISMS AND THERAPEUTIC OPPORTUNITIES**

February 27–March 2, 2000
Hyatt Regency Lake Tahoe Resort, Lake Tahoe, NV

Chairpersons
John C. Reed, La Jolla, CA
Junying Yuan, Charlestown, MA

**MELANOMA: BASIC BIOLOGY AND IMMUNOLOGICAL APPROACHES TO THERAPY**

May 3–7, 2000
The Woodlands Resort, The Woodlands, TX

Chairperson
Mehnadt Herlyn, Philadelphia, PA
Giorgio Parmiani, Milan, Italy

**CYTOKINES AND CANCER: REGULATION, ANGIOGENESIS, AND CLINICAL APPLICATIONS**

September 20–24, 2000
Vail Cascade Hotel & Club, Vail, CO

Chairpersons
Janice P. Dutcher, Bronx, NY
Michael Lotze, Pittsburgh, PA
Giorgio Trinchieri, Philadelphia, PA

**ANGIOGENESIS**

October 11–15, 2000
Grand Traverse Resort, Traverse City, MI

Chairpersons
Judah Folkman, Boston, MA
David A. Cheresh, La Jolla, CA

**NEW TARGETS FOR CANCER INTERVENTION**

(Left-sponsored by the Israeli Cancer Society)
November 12–15, 2000
Royal Beach Hotel, Eilat, Israel

Chairpersons
Webster K. Cavenee, La Jolla, CA
Pnina Fishman, Petah Tikua, Israel

**MOUSE MODELS OF CANCER**

November 29–December 3, 2000
Hyatt Regency, La Jolla, CA

Chairpersons
Tyler Jacks, Cambridge, MA
Ronald A. DePinho, Boston, MA

**RECENT DEATHS**

We regret to report the deaths of Dr. Fritz Anders of Giessen, Germany; Dr. Paul A. Basset of Illkirch Cedex, France; Dr. Daisilee H. Berry of Roland, AR; Dr. Felix D. Bertalanffy of Winnipeg, Manitoba, Canada; Dr. Leila Diamond of Solebury, PA; Dr. Gustave Freeman of Oakland, CA; Dr. Ludwik Gross of Bronx, NY; Dr. Dezider Grunberger of New York, NY; Dr. Katharine P. Hummel of Bar Harbor, ME; Dr. Joseph Leighton of Oakland, CA; Dr. J. Murray Luck of Fremont, CA; Dr. Gerald P. Murphy of Seattle, WA; Dr. Takis S. Papas of Charleston, SC; Dr. Dorothy R. Pikelka of Berkeley, CA; Dr. David P. Rall of Washington, D.C.; Dr. Sydney E. Salmon of Tucson, AZ; Dr. P. G. Satyaswaroop of Hershey, PA; Dr. John Albert Schilling of Seattle, WA; Dr. Samuel Schwartz of Minneapolis, MN; Dr. Oleg S. Selawry of Rileyville, VA; Dr. Peter A. Steck of Houston, TX; Dr. John H. Van Dyke of Telford, PA; and, Dr. Ernst L. Wynder of New York, NY. Drs. Anders, Berry, Bertalanffy, Diamond, Freeman, Grunberger, Hummel, Leighton, Luck, Pikelka, Rall, Schilling, Schwartz, Selawry, and Van Dyke were Emeritus Members; Dr. Basset was a Corresponding Member; Drs. Gross and Wynder were Honorary Members; and, Drs. Murphy, Papas, Salmon, Satyaswaroop, and Steck were Active Members of the American Association for Cancer Research.

**CALENDAR OF EVENTS**

**IBC’s 9th Annual International High-Throughput Screening Symposium, February 28–29, 2000, Hyatt Regency Monterey, Monterey, CA 93940-4908. Contact: IBC USA Conferences Inc., 225 Tumpke Road, Southborough, MA 01772-1749. Phone: (508) 481-6400; Fax: (508) 481-7911; E-mail: reg@ibcusas.com; Website: www.ibc-lifesci.com/screentech.**

International Conference on Advances in Cancer Immunotherapy, March 2–4, 2000, Princeton, NJ. Abstract deadline: October 1, 1999. Contact: Lois Gillespie, Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109. Phone: (973) 844-7007; Fax: (973) 844-7020; Email: gsccancer@att.net.

First International Conference on Translational Research and Pre-Clinical Strategies in Radio-Oncology, May 5–8, 2000, Palazzo dei Congressi Conference Center, Lugano Switzerland. Contact: Dr. Jacques Bernier, Can- tonal Department of Radio-Oncology, Sand Giovanni Hospital, CH-6504 Bellinzona, Switzerland. Phone: 41 91 820 91 57; Fax: 41 91 820 90 44; jbernier@cscs.ch; Website: http://www.osg.ch/ictr2000.html.


Annual Meeting of the American Society for Blood and Marrow Transplantation, March 29–April 1, 2000, Anaheim, CA. Contact: IBMTR/ABMTR Statistical Analysis, 1148 Woodgate Lane, McLean, VA 22101. Phone: (703) 847-6666; Fax: (703) 847-6667; E-mail: clinreview@erols.com.

International Conference on Advances in Cancer Immunotherapy, March 2–4, 2000, Princeton, NJ. Abstract deadline: October 1, 1999. Contact: Lois Gillespie, Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109. Phone: (973) 844-7007; Fax: (973) 844-7020; Email: gsccancer@att.net.

First International Conference on Translational Research and Pre-Clinical Strategies in Radio-Oncology, May 5–8, 2000, Palazzo dei Congressi Conference Center, Lugano Switzerland. Contact: Dr. Jacques Bernier, Can- tonal Department of Radio-Oncology, Sand Giovanni Hospital, CH-6504 Bellinzona, Switzerland. Phone: 41 91 820 91 57; Fax: 41 91 820 90 44; jbernier@cscs.ch; Website: http://www.osg.ch/ictr2000.html.
IX International Symposium on Luminescence Spectrometry in Biomedical and Environmental Analysis – Spectroscopic and Imaging Detection Techniques, May 15–17, 2000, CORUM, Centre des Congrès, France. Contact: Dr. Dan A. Lerner, Chairman, University of Montpellier, Ecole Nationale Supérieure de Chimie 8, Rue de l’Ecole Normale, F-34296 Montpellier cedex 5, France. Phone: 33-04 6714 4323; Fax: 33-04 6714 4349; Email: lerner@enscm.fr.

IX International Symposium on Luminescence Spectrometry in Biomedical and Environmental Analysis – Spectroscopic and Imaging Detection Techniques, May 15–17, 2000, CORUM, Centre des Congrès, France. Contact: Dr. Dan A. Lerner, Chairman, University of Montpellier, Ecole Nationale Supérieure de Chimie 8, Rue de l’Ecole Normale, F-34296 Montpellier cedex 5, France. Phone: 33-04 6714 4323; Fax: 33-04 6714 4349; Email: lerner@enscm.fr.

IX International Symposium on Luminescence Spectrometry in Biomedical and Environmental Analysis – Spectroscopic and Imaging Detection Techniques, May 15–17, 2000, CORUM, Centre des Congrès, France. Contact: Dr. Dan A. Lerner, Chairman, University of Montpellier, Ecole Nationale Supérieure de Chimie 8, Rue de l’Ecole Normale, F-34296 Montpellier cedex 5, France. Phone: 33-04 6714 4323; Fax: 33-04 6714 4349; Email: lerner@enscm.fr.

IX International Symposium on Luminescence Spectrometry in Biomedical and Environmental Analysis – Spectroscopic and Imaging Detection Techniques, May 15–17, 2000, CORUM, Centre des Congrès, France. Contact: Dr. Dan A. Lerner, Chairman, University of Montpellier, Ecole Nationale Supérieure de Chimie 8, Rue de l’Ecole Normale, F-34296 Montpellier cedex 5, France. Phone: 33-04 6714 4323; Fax: 33-04 6714 4349; Email: lerner@enscm.fr.

IX International Symposium on Luminescence Spectrometry in Biomedical and Environmental Analysis – Spectroscopic and Imaging Detection Techniques, May 15–17, 2000, CORUM, Centre des Congrès, France. Contact: Dr. Dan A. Lerner, Chairman, University of Montpellier, Ecole Nationale Supérieure de Chimie 8, Rue de l’Ecole Normale, F-34296 Montpellier cedex 5, France. Phone: 33-04 6714 4323; Fax: 33-04 6714 4349; Email: lerner@enscm.fr.

IX International Symposium on Luminescence Spectrometry in Biomedical and Environmental Analysis – Spectroscopic and Imaging Detection Techniques, May 15–17, 2000, CORUM, Centre des Congrès, France. Contact: Dr. Dan A. Lerner, Chairman, University of Montpellier, Ecole Nationale Supérieure de Chimie 8, Rue de l’Ecole Normale, F-34296 Montpellier cedex 5, France. Phone: 33-04 6714 4323; Fax: 33-04 6714 4349; Email: lerner@enscm.fr.

IX International Symposium on Luminescence Spectrometry in Biomedical and Environmental Analysis – Spectroscopic and Imaging Detection Techniques, May 15–17, 2000, CORUM, Centre des Congrès, France. Contact: Dr. Dan A. Lerner, Chairman, University of Montpellier, Ecole Nationale Supérieure de Chimie 8, Rue de l’Ecole Normale, F-34296 Montpellier cedex 5, France. Phone: 33-04 6714 4323; Fax: 33-04 6714 4349; Email: lerner@enscm.fr.
Errata

In the article by C. Koike et al., entitled “Sensitivity to polyamine-induced growth arrest correlates with antizyme induction in prostate carcinoma cells,” which was published in the December 15, 1999 issue of Cancer Research (pp. 6109–6112), the first author’s name was spelled incorrectly. The correct spelling is Chieko Koike.

In the article by K. M. Henkels and J. J. Turchi entitled “Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines,” which appeared in the July 1, 1999 issue of Cancer Research (pp. 3077–3083), the legend to Figure 1 appeared incorrectly. The correct legend and corresponding Figure 1 are as follows:

![Figure 1](image1)

**Fig. 1.** Expression of caspase-3 in cisplatin-sensitive and -resistant human ovarian cancer cell lines prior to and following cisplatin treatment. Twenty μg of protein from each cell-free extract were separated by SDS-PAGE and transferred to Immobilon-P membranes, as described in “Materials and Methods.” Western blots were probed with a 1:1000 dilution of the mouse monoclonal IgG anti-CPP32 antibody. Antibody reactivity was detected using Renaissance chemiluminescence reagents after a 1:3000 dilution of the secondary HRP-conjugated antibody. Lanes 1, 4, and 7, untreated adherent, IC₅₀ and IC₉₀ cisplatin-treated nonadherent A2780 cells, respectively; Lanes 2, 5, and 8, untreated adherent, IC₅₀ and IC₉₀ cisplatin-treated nonadherent CP70 cells, respectively; and Lanes 3, 6, and 9, untreated adherent, IC₅₀ and IC₉₀ cisplatin-treated nonadherent C30 cells, respectively. The positions of relative molecular weight standards are represented on the left, whereas the position of the full-length caspase-3 molecule (p32) and its proteolyzed fragments (p20 and p17, respectively) are denoted on the right by arrows.

In the article by D-C. Yu et al., entitled “The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts,” which appeared in the September 1, 1999 issue of Cancer Research (pp. 4200–4203), Figure 8 appeared incorrectly. The correct Figure 8 and corresponding legend are as follows:

![Figure 8](image2)

**Fig. 8.** LNCaP xenograft tumors in nu/nu mice following on i.v. tail vein injection of CV787. A, tumor size, measured weekly. B, serum PSA, measured weekly by immunosassay. C, replication of adenovirus in LNCaP tumors determined by immunohistochemistry with rabbit polyclonal antibody to Ad5.
Errata

Cancer Res 2000;60:1150.

Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/60/4/1150

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.